<DOC>
	<DOCNO>NCT01677039</DOCNO>
	<brief_summary>The study design test whether rate extent absorption oxycodone proprietary controlled-release formulation significantly affect co-administration alcohol compare controlled condition ( formulation administer water ) . The primary pharmacokinetic parameter peak concentration oxycodone ( Cmax ) overall exposure level oxycodone represent area plasma concentration-time curve ( AUC ) .</brief_summary>
	<brief_title>Study Determine Effects Co-Administration Alcohol Absorption Oxycodone From Proprietary Controlled-Release Formulation</brief_title>
	<detailed_description />
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>healthy volunteer history moderate alcohol consumption total body weight exceed 64 kg history clinically significant disease history sleep apnea condition affect drug absorption pregnant nursing female subject history allergy hypersensitivity either oxycodone naltrexone</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Bioavailability</keyword>
	<keyword>oxycodone</keyword>
	<keyword>ethanol interaction</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>